Advik Laboratories Ltd.
Snapshot View

1.11 0.00

02 August 2021, 04:00:00 P.M.
Volume: 890

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.advikindia.com
Financial Indicators
Market Cap 2.12 Cr.
Earnings per share (EPS) -2.31 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 2.07 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.54 Calculated using Price: 1.11
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.91 Cr. 19,111,400 Shares
FaceValue 10
Company Profile

Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.

Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.

The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.

The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.

With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.

Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.

Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.

Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.

Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+4.72%
3 Month
+9.90%
6 Month
+208.33%
1 Year
+208.33%
2 Year
+7.77%
5 Year
-78.36%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 0.03 4.55 3.24 -4.03 -6.79 -48.30 -7.74 -12.28 -13.04
Return on Capital Employed (%) 4.55 10.30 8.13 0.59 -4.23 -33.90 -5.91 -7.76 -8.08
Return on Assets (%) 0.01 1.89 1.45 -2.01 -3.91 -29.85 -4.32 -6.79 -6.87

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 11 11 20 19 19 12 11 10 8
Non Curr. Liab. 8 10 4 3 2 1 1 1 1
Curr. Liab. 5 8 10 10 7 8 8 7 7
Minority Int.
Equity & Liab. 24 29 35 32 29 21 19 18 16
Non Curr. Assets 11 10 16 15 15 14 13 12 11
Curr. Assets 13 19 19 17 14 7 7 5 5
Misc. Exp. not W/O
Total Assets 24 29 35 32 29 21 19 18 16

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 20 34 30 12 1 3 4 1
Other Income 0 0 0 0 0 0 0
Total Income 20 34 30 12 1 3 4 1 0
Total Expenditure -19 -31 -27 -11 -2 -10 -5 -2 -1
PBIDT 1 3 3 1 0 -7 0 -1 -1
Interest -1 -1 -1 -1 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation 0 -1 -1 0 0 0 0 0 0
Exceptional Items
PAT 1 0 -1 -1 -7 -1 -1 -1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -2 0 5 2 1 0 0 1 0
Cash Fr. Inv. 0 0 -6 0 0 1 0 0 0
Cash Fr. Finan. 2 0 2 -2 -1 -1 0 0
Net Change 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 35.89 35.89 35.89 35.89 35.89 35.89 35.89 35.89 35.89
Public 64.11 64.11 64.11 64.11 64.11 64.11 64.11 64.11 64.11
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 71.16 71.16 71.16 71.16 71.16 71.16 71.16 16.04 16.04

Announcements View Details

Tue, 27 Jul 2021
Board Meeting Intimation for Notice Of Board Meeting To Consider Un-Audited Financial Results Of The Company For The Quarter Ended 30Th June 2021
ADVIK LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2021 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations 2015 notice is hereby given that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations 2015 a meeting of the Board of Directors of the company is scheduled to be held on Wednesday 04th August 2021 at the corporate office of the company at 703 Arunachal Building 19 Barakhambha Road Connaught Place New Delhi-110001 to inter-alia consider and approve the Un-Audited Financial Results of the Company for the quarter ended June 30 2021 and to carry on any other business with the permission of the Board.
Thu, 15 Jul 2021
Shareholding for the Period Ended June 30 2021
Advik Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 13 Jul 2021
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Patliputra International Ltd

Technical Scans View Details

Mon, 02 Aug 2021
Opening at High Opening at High
Opening at Low Opening at Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
MFI Above 80 MFI Above 80
Mon, 26 Jul 2021
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 774.45 +0.1%
Divi's Laboratories Ltd. 130,822.92 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,701.80 -0.2%
Cipla Ltd. 74,356.30 921.80 +0.2%
Cadila Healthcare Ltd. 60,574.85 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,049.00 +0.4%
Piramal Enterprises Ltd. 56,317.82 2,480.15 +7.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.92 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,480.15 +7.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.06 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,480.15 +7.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,480.15 +7.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,480.15 +7.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,480.15 +7.0%